
TCR2 Therapeutics Inc, an immuno-oncology (I-O) company claiming to be developing a new class of T cell receptor (TCR)-based cellular therapies for both solid tumors and blood cancers, has completed an oversubscribed Series B financing of $125 million.
The funds will advance the US biotech’s TRuC-T cell programs through human proof-of-concept, including its lead solid tumor program TC-210 targeting mesothelin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze